Research programme: attention deficit hyperactivity disorder therapies - Sosei

Drug Profile

Research programme: attention deficit hyperactivity disorder therapies - Sosei

Alternative Names: Bifemelane hydrochloride; SON-216

Latest Information Update: 27 Feb 2008

Price : $50

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Sosei
  • Class Benzhydryl compounds
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Attention-deficit hyperactivity disorder

Most Recent Events

  • 02 Jun 2005 Preclinical trials in Attention-deficit hyperactivity disorder in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top